Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer

BACKGROUND: Bevacizumab in combination with chemotherapy prolonged the progression-free survival (PFS) of patients with recurrent epithelial ovarian cancer (EOC) in large-scale randomized controlled trials. However, real-world data for the use of bevacizumab in Asian patients with EOC is lacking. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Jo-Ni, Hsu, Shih-Tien, Sun, Lou, Hwang, Sheau-Feng, Liu, Chih-Ku, Shih, Yu-Hsiang, Chen, Ming-Jer, Wang, Jun-Sing, Lu, Chien-Hsing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160985/
https://www.ncbi.nlm.nih.gov/pubmed/35664738
http://dx.doi.org/10.3389/fonc.2022.843278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160985/
https://www.ncbi.nlm.nih.gov/pubmed/35664738
http://dx.doi.org/10.3389/fonc.2022.843278

Ejemplares similares